Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNF2024 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Patients with HER2- Breast Cancer |
| B | EXPERIMENTAL | Patients with HER2+ Breast Cancer |
| Dosing Schedule 1 | OTHER | Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed. |
| Dosing Schedule 2 | OTHER | Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2). |
| Name | Type | Description |
|---|---|---|
| CNF2024 | DRUG | Oral doses of CNF2024 as specified in the protocol. |
| CNF2024 + trastuzumab | DRUG | Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert. |
Inclusion Criteria (Group A): * Age ≥18 years at the time of informed consent. * Male and female subjects with confirmed HER2 adenocarcinoma of the breast with advanced disease (advanced disease will be defined as metastatic disease or locally advanced disease that is surgically unresectable and co...
Top 20 of 92 competitors
CNF2024 is an investigational small molecule being studied for the treatment of breast cancer and tumors. It was evaluated in Phase 1 clinical trials for advanced solid tumors and breast cancer, including in combination with Herceptin for HER2-positive breast cancer.
CNF2024 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The drug is an investigational small molecule in the oncology therapeutic area.
CNF2024 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in advanced solid tumors and one in breast cancer. The drug is investigational and has not been approved by the FDA.
CNF2024 has been studied in two completed Phase 1 trials. NCT00345189 evaluated oral CNF2024 in 70 patients with advanced solid tumors or lymphoma. NCT00412412 studied CNF2024 in 34 breast cancer patients, including a HER2-negative arm and a HER2-positive arm with Herceptin.
Yes, CNF2024 is also known as BIIB021. Clinical trial records refer to the drug as both CNF2024 and BIIB021, such as in the studies NCT00345189 and NCT00412412.